A Phase 2 Randomized, Double-Blind, Placebo–Controlled Study of the Safety and Efficacy of Talactoferrin in Patients with Severe Sepsis

  • TLF LF-0801 Investigator Group
  • , Kalpalatha Guntupalli
  • , Nathan Dean
  • , Peter E. Morris
  • , Venkata Bandi
  • , Benjamin Margolis
  • , Emanuel P. Rivers
  • , Mitchell Levy
  • , Robert F. Lodato
  • , Preeti M. Ismail
  • , Amber Reese
  • , John P. Schaumberg
  • , Rajesh Malik
  • , R. Phillip Dellinger

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
Pages (from-to)706-716
Number of pages11
JournalCritical Care Medicine
Volume41
Issue number3
DOIs
StatePublished - Mar 2013

ASJC Scopus Subject Areas

  • Critical Care and Intensive Care Medicine

Keywords

  • Lactoferrin
  • Septic shock
  • Severe sepsis
  • Talactoferrin alfa

Cite this